
The US fertility rate reached a new low in 2024, CDC data shows
The U.S. was once among only a few developed countries with a rate that ensured each generation had enough children to replace itself — about 2.1 kids per woman. But it has been sliding in America for close to two decades as more women are waiting longer to have children or never taking that step at all.
The new statistic is on par with fertility rates in western European countries, according to World Bank data.
Alarmed by recent drops, the Trump administration has taken steps to increase falling birth rates, like issuing an executive order meant to expand access to and reduce costs of in vitro fertilization and backing the idea of 'baby bonuses' that might encourage more couples to have kids.
But there's no reason to be alarmed, according to Leslie Root, a University of Colorado Boulder researcher focused on fertility and population policy.
'We're seeing this as part of an ongoing process of fertility delay. We know that the U.S. population is still growing, and we still have a natural increase — more births than deaths,' she said.
The U.S. Centers for Disease Control and Prevention released the statistic for the total fertility rate with updated birth data for 2024.
In the early 1960s, the U.S. total fertility rate was around 3.5, but plummeted to 1.7 by 1976 after the Baby Boom ended. It gradually rose to 2.1 in 2007 before falling again, aside from a 2014 uptick. The rate in 2023 was 1.621, and inched down in 2024 to 1.599, according to the CDC 's National Center for Health Statistics.
Birth rates are generally declining for women in most age groups — and that doesn't seem likely to change in the near future, said Karen Guzzo, director of the Carolina Population Center at the University of North Carolina.
People are marrying later and also worried about their ability to have the money, health insurance and other resources needed to raise children in a stable environment.
'Worry is not a good moment to have kids,' and that's why birth rates in most age groups are not improving, she said.
Asked about birth-promoting measures outlined by the Trump administration, Guzzo said they don't tackle larger needs like parental leave and affordable child care.
'The things that they are doing are really symbolic and not likely to budge things for real Americans,' she said.
Increase in births in new data
The CDC's new report, which is based on a more complete review of birth certificates than provisional data released earlier this year, also showed a 1% increase in births — about 33,000 more — last year compared to the prior year.
That brought the yearly national total to just over 3.6 million babies born.
But this is different: The provisional data indicated birth rate increases last year for women in their late 20s and 30s. However, the new report found birth rate declines for women in their 20s and early 30s, and no change for women in their late 30s.
What happened? CDC officials said it was due to recalculations stemming from a change in the U.S. Census population estimates used to compute the birth rate.
That's plausible, Root said. As the total population of women of childbearing age grew due to immigration, it offset small increases in births to women in those age groups, she said.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Reuters
21 minutes ago
- Reuters
UnitedHealth forecasts annual profit below estimates
July 29 (Reuters) - UnitedHealth on Tuesday reinstated full-year profit forecast that it pulled over two months ago, but its guidance fell short of analysts' already-lowered expectations, as the U.S. health insurer battles rising costs in its government-backed plans. The company (UNH.N), opens new tab, which has seen a series of setbacks this year, also missed Wall Street expectations for second-quarter earnings. The results show the scale of the challenges UnitedHealth's new CEO Stephen Hemsley is facing after being restored to the role in May following the abrupt resignation of incumbent Andrew Witty. Its shares fell 5% in premarket trading after the company said its new forecast reflects expectations for higher realized and anticipated care trends. UnitedHealth suspended its 2025 forecast in May, a historic first for the insurer, citing higher-than-anticipated medical expenditures, which have also rattled its peers. The company on Tuesday forecast annual profit of at least $16 per share, lower than its previous expectation of $26 to $26.50 per share. Analysts on average were expecting a profit of $20.91 per share, per LSEG data. The healthcare conglomerate reiterated that it expects to return to earnings growth in 2026. The company's adjusted second-quarter profit of $4.08 per share missed analysts' average estimate of $4.48.


Reuters
an hour ago
- Reuters
Philips cuts tariff impact estimate following US-EU deal, shares up 10%
July 29 (Reuters) - Dutch healthcare technology company Philips ( opens new tab slashed its estimated tariff impacton Tuesday after the United States and the European Union agreed a trade dealthat imposes a 15% rate on most goods imported from Europe. U.S. President Donald Trump had threatened to impose a 30% tariff on imports from the 27-nation EU bloc from August 1 in the absence of an agreement. The group, which sells products ranging from toothbrushes to medical imaging systems, said it expected an impact of 150 million to 200 million euros ($173 million to $232 million) from the tariffs this year, lower than the 250 million to 300 million euros it had previously estimated. Philips' Amsterdam-listed stock was the top performer on the pan-European STOXX index (.STOXX), opens new tab in early Tuesday trading, climbing 10% by 0930 GMT. Philips CEO Roy Jakobs told reporters that the U.S.-EU deal provided clarity, but Philips would continue to ask for an exemption from tariffs and other trade barriers for the healthcare sector, including in the U.S. and in China. China announced earlier this month it was restricting government purchases of medical devices from the EU that exceed 45 million yuan ($6.27 million) in value, in retaliation against Brussels' own curbs imposed in June. "We have localized 90% of what we sell in China to manufacture in China, so this is not something of significance to us," Jakobs said, adding that the Chinese market was slowly recovering. Philips also increased its core profit (EBITA) margin forecast to a range of 11.3% to 11.8% for the year, from the previous guidance of 10.8% to 11.3%. Chief Financial Officer Charlotte Hanneman told analysts that the company expects mid-single-digit growth and mid-teens margins beyond 2025, taking into account the impact of tariffs. Its second-quarter adjusted EBITA margin grew to 12.4%, beating analysts' average forecast of 9.9%, while sales were in line with market expectations at 4.3 billion euros. Philips operates through its Personal Health, Diagnosis & Treatment, and Connected Care segments. Its top selling products include image-guided and diagnostic systems, consumer electronics and appliances. The company's sleep and respiratory care products, part of its Connected Care segment, accounted for about 6% of its total sales in 2024. That is about half their pre-pandemic levels, following a 2021 recall of millions of breathing devices and ventilators used to treat sleep apnea. Philips said last April it had agreed to pay $1.1 billion, less than expected, in a settlement of personal injury cases in the United States related to the recall. It said it was committed to rebuilding its position in the market while resolving the effects of the recall. "We have strong momentum in the masks ... and we are working our way back into the markets that we are reentering", Jakobs told analyst on Tuesday. Its comparable order intake grew by 6% in the quarter, the company said, citing the impact of innovations including AI-enabled diagnostic systems. The group also said it had signed a long-term deal with the Indonesian Ministry of Health for its Azurion image-guided therapy system for cardiac, stroke and cancer care and expected a "sizable" impact on its revenues over time. ($1 = 0.8630 euros) ($1 = 7.1764 Chinese yuan renminbi)


Reuters
an hour ago
- Reuters
AstraZeneca tops expectations on robust drug sales, US demand
July 29 (Reuters) - AstraZeneca (AZN.L), opens new tab on Tuesday beat second-quarter revenue and profit expectations on robust sales of newer cancer, heart and kidney disease medicines and strong demand in the U.S., where it has invested $50 billion to expand amid tariff threats from Washington. The performance is a boost for the UK's largest-listed company by market value as the wider sector braces for U.S. tariffs on pharmaceutical imports and navigates pressure after President Donald Trump's order pushing for drugmakers to cut U.S. prices to what other countries pay. AstraZeneca shares rose as much as 3% to about 111 pounds by 0923 GMT, hitting their highest since early April. The drugmaker in April forecast only a limited impact from potential U.S. tariffs, adding it would be able to meet its annual outlook if the levies on European imports were similar to those in other industries. A European Union-U.S. trade deal over the weekend will result in a 15% tariff on pharmaceuticals from the region. The U.S. accounted for more than 40% of AstraZeneca's revenue in 2024. The company had prioritised the market - the world's largest, worth $635 billion - even before Trump's return to office. Novartis (NOVN.S), opens new tab this month also said potential new U.S. tariffs would not affect its 2025 guidance, and J&J (JNJ.N), opens new tab halved its expectations for costs this year related to new levies and raised its full-year forecasts. However, Abbott(ABT.N), opens new tab flagged an over $1 billion hit in 2025 from the duties and a drop in demand for COVID tests. AstraZeneca is betting on a wave of expected launches of 20 new medicines and its U.S. expansion to reach $80 billion in annual revenue by 2030 and offset generic competition. On Tuesday, it maintained its 2025 outlook and increased its interim dividend by 3%. "Our strong momentum in revenue growth continued through the first half of the year and the delivery from our broad and diverse pipeline has been excellent," CEO Pascal Soriot said. Sales of oncology drugs, constituting nearly half of AstraZeneca's revenue, were up 18% at $6.31 billion at constant currency rates in the quarter. Jefferies analysts said sales of drugs including Tagrisso, Lynparza, Calquence, Truqap and Imfinzi beat expectations. Total revenue for the three months ended June grew 11% to $14.46 billion, with double-digit growth in the U.S. despite headwinds from changes in U.S. Medicare price negotiations. Core earnings stood at $2.17 per share. That compares with analysts' expectations of $2.16, and $14.15 billion in sales, according to a company-provided consensus. "Operationally, this is the type of quarter we want to see," Barclays analysts said. AstraZeneca is also hoping to move on from scandals in its second-biggest market, China, where it this year faced minor fines related to cancer drugs. It is also fighting patent challenges from an individual against Tagrisso. The company also delayed late-stage AVANZAR trial data for a key lung cancer treatment to the first half of 2026.